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Background: Mesenchymal stem cell therapy improves ischemic heart failure via incompletely understood
mechanisms. C1q-TNFα related protein-9 (CTRP9) is a novel anti-oxidative cardiokine capable of improving the
local microenvironment and cell survival by its c-terminal active globular domain (gCTRP9). The current study
attempted to: 1) identify active gCTRP9 c-terminal polypeptides with stem cell protective function; 2) determine
whether a lead polypeptide may enable/enhance cortical bone-derived mesenchymal stem cell (CBSC) car
dioprotection against post-myocardial infarction (post-MI) remodeling; and 3) define the responsible underlying
cellular/molecular mechanisms.
Methods and results: Utilizing I-TASSER structure prediction and 3-D active site modeling, we cloned and purified
3 gCTRP9 fragments (CTRP9-237, CTRP9-277, and CTRP9-281). Their activation of cell salvage kinase was
compared against gCTRP9. Among the three fragments, CTRP9-281 (a 45 residue-containing polypeptide)
exerted comparable or greater ERK1/2 activation compared to gCTRP9. Treatment with CTRP9-281 or gCTRP9
significantly increased CBSC proliferation and migration, and attenuated oxidative stress-induced CBSC
apoptosis. CTRP9-281 and gCTRP9 comparably upregulated SOD2 and SOD3 expression. However, CTRP9-281,
not gCTRP9, upregulated FGF2 and VEGFA expression/secretion in an ERK1/2 dependent manner. Adminis
tration of gCTRP9 or CTRP9-281 alone attenuated post-MI cardiac dysfunction and improved CBSC retention in
the infarcted heart in similar fashion. However, CTRP9-281 exerted greater synergistic effect with CBSC than
gCTRP9 related to pro-angiogenic, anti-fibrotic, and anti-remodeling effects. Mechanistically, CTRP9-281
significantly increased SOD2-rich and VEGFA-rich exosome production by CBSC. Exosomes from CTRP9-281
treated CBSC significantly attenuated oxidative stress-induced cardiomyocyte apoptosis in vitro. An exosome
generation inhibitor attenuated CTRP9-281 enhancement of CBSC cardioprotection in vivo.
Conclusion: We identified a CTRP9 polypeptide that upregulates SOD2/SOD3 expression and improves CBSC
survival/retention, similar to gCTRP9. Moreover, CTRP9-281 stimulates VEGFA-rich exosome production by
CBSC, exerting superior pro-angiogenic, anti-fibrotic, and cardioprotective actions.
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Fig. 1. CTRP9-281, a 45 residues-containing polypeptide, possesses cellular salvage kinase activation property and improves CBSC function comparable
as that of gCTRP9. A/B: Effect of gCTRP9, CTRP9-237, CTRP9-277 and CTRP9-281 (2 μg/mL for 15 min) on cell salvage kinase activation in CBSC. n = 4/group,
**P < 0.01 vs. vehicle. C: CBSCs proliferation curves (n = 12/group, **P < 0.01 vs. vehicle at indicated time. D/E, Wound healing assay was performed 24 h after
vehicle, gCTRP9 or CTRP9-281 treatment. n = 6/group *P < 0.05 vs. vehicle. F-I: CBSCs apoptosis was determined by TUNEL staining and caspase cleavage. CBSCs
were treated with 2 μg/mL gCTRP9 or 2 μg/mL CTRP9-281 for 24h followed by H2O2 for 2 h n = 6/group. *P < 0.05, **P < 0.01 vs. vehicle. DAPI, 4′ -6-diamidino-2phenylindole; gCTRP9, globular domain isoform of C1q/tumor necrosis factor–related protein-9; CTRP9-281, 45 residues-containing polypeptides of gCTRP9; O.D.,
optical density; and TUNEL, transferase-mediated dUTP nick-end labeling.

1. Introduction

clinical trials evaluating the efficacy of MSC in patients with acute
myocardial infarction injury or decompensated IHF have been indeter
minate [3]. Therapeutic strategies enhancing cell therapy efficacy are in
great demand.
The most significant limitation for MSC therapy in IHF remains poor
retention/survival of engrafted cells [4,5]. MI creates a harsh microen
vironment with increased oxidative stress, limited nutrients, and oxygen
dearth, inducing damage and death of delivered cells [6,7]. Overcoming
this limitation by either promoting MSC survival or improving the local

Cardiovascular disease accounts for the greatest proportion of pre
mature mortality and morbidity of any noncommunicable disease.
Ischemic heart disease, such as myocardial infarction, is the largest
contributor to the epidemic of cardiovascular diseases. Adult mamma
lian hearts have limited regenerative capacity. A decade’s worth of ev
idence supports transplantation of mesenchymal stem cells (MSC) as a
potential therapeutic for ischemic heart failure (IHF) [1,2]. However,
2
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environment may help make cell therapy a reality for myocardial
infarction [8]. The mechanisms underlying MSC activity in injured
myocardium have been extensively studied. Although it was once
believed that MSCs could generate new cardiac tissue, evidence now
demonstrates de novo cardiomyocyte regeneration does not occur after
MSC administration. The cardioprotective effects of MSC are attributed
to secretion of immunomodulatory, anti-autophagic, anti-apoptotic, and
pro-angiogenic factors [9–11]. Molecules capable of improving the MSC
cardioprotective secretome may enhance cell therapy efficacy against
IHF.
The C1q/TNF-related proteins (CTRPs) are a protein family consist
ing of fifteen (CTRP1-CTRP15) identified adiponectin paralogs [12]. We
and others recently demonstrate that CTRP9 is a cardiokine, as it has the
greatest expression level in the adult heart [13–15]. MI significantly
inhibits myocardial CTRP9 (both mRNA and protein) expression, and
reduces plasma CTRP9 levels [16,17]. CTRP9 is critical in maintaining a
healthy local environment in the ischemic heart, enhancing intra
myocardial injected adipocyte MSC (ADSC) survival, enabling their
cardioprotection [5]. Importantly, the c-terminal globular domain iso
form of CTRP9 (gCTRP9, residues 197-333), but not full length CTRP9,
activates key cell salvage kinases and functions as the active car
dioprotective isoform [13,18]. However, whether there exist c-terminal
polypeptides retaining g-CTRP9 activity remains unclear. Producing
biologically active proteins is difficult, and optimizing the dosage and
route of recombinant protein administration is complex. Designing
active CTRP9 polypeptides is a highly desirable strategy in realizing the
beneficial effects of CTRP9.
Therefore, the aims of the present study were 1) investigating
whether gCTRP9-derived polypeptides may exert similar or better stem
cell protective function than gCTRP9; 2) determining whether a lead
polypeptide may enable/enhance CBSC cardioprotection against postMI pathological remodeling, and 3) defining the underlying cellular/
molecular mechanisms.

analysis. Fibrosis was evaluated by Masson’s trichrome staining. More
detailed materials and methods are presented in the online-only Data
Supplement.
2.3. Statistical analysis
Data are reported as mean ± SEM. The Kaplan-Meier survival curves
were analyzed by a Gehan-Breslow-Wilcoxon test. For analysis of dif
ferences between 2 groups, the unpaired Student t-test was performed.
For multiple groups, 1-way ANOVA was performed, followed by Bon
ferroni post hoc test. For multiple groups over time or for testing the
interaction of CTRP9/CBSC therapy on heart function after MI, 2-way
ANOVA was performed, followed by Bonferroni post hoc test. P
values < 0.05 were considered significant. In this study, n is the number
of animals or cell cultures tested.
3. Results
3.1. Identification of a CTRP9 polypeptide activating cellular salvage
kinases, improving CBSC function via novel mechanism
We and others have previously demonstrated that gCTRP9 (residues
197-333) is the active isoform of CTRP9. To maximize CTRP9 trans
lational application, we attempted to identify gCTRP9 polypeptides with
capability of activating protective intracellular signaling. Based on the ITASSER structure prediction and three dimensional modeling of the
active site using cofactor and coach [19], we cloned and purified 3
gCTRP9 fragments (CTRP9-237, CTRP9-277, and CTRP9-281, patent
pending). In a recent study, we demonstrate that gCTRP9 kinase acti
vation is cell-type dependent [5]. Specifically, gCTRP9 activates multi
ple cell salvage kinases, including ERK1/2, Akt, and AMPK in adult
cardiomyocyte via binding with AdipoR1. However, AdipoR1 expres
sion is low in mesenchymal stem cells and gCTRP9 activates ERK1/2
(not Akt and AMPK) in ADSC via binding with N-cadherin [5]. To
determine whether CTRP9 fragments retain gCTRP9 kinase activation
profile, we compared the effect of gCTRP9 fragments upon cell salvage
kinases against gCTRP9. In H9C2 cells, CTRP9 fragments activated all
three cell salvage kinases similar as gCTRP9 (data not shown). More
importantly, all three CTRP9 fragments significantly and selectively
activated ERK1/2 in CBSC, a property shared with their parent protein,
gCTRP9 (Fig. 1A and B). Among these three fragments, CTRP9-281 ex
erts the best ERK1/2 activation (although not statistically different).
Importantly, CTRP9-281 is the shortest fragment and qualifies as a
polypeptide (45 aa residue). Finally, no cardiovascular cytotoxic effect
(including blood pressure, heart rate, left ventricular function, and
hs-cTnT) was observed after bolus administration of CTRP9-281 at 5-50
μg/g (tail vein). CTRP9-281 was therefore our prime molecule of
investigation concerning CBSC function and synergistic car
dioprotection. We have recently demonstrated that gCTRP9 signifi
cantly improves ADSC function. To determine whether CTRP-281 (a
polypeptide with better translational value) may improve CBSC (a stem
cell type investigated clinically) function, we examined the effect of
CTRP9-281 upon CBSC proliferation, migration, and oxidative
stress-induced apoptosis. CTRP9-281 increased CBSC proliferation to
slightly greater extent compared to gCTRP9 (Cell Counting Kit assay,
Fig. 1C). Treatment of CBSC for 14 h with either CTRP9-281 or gCTRP9
significantly enhanced migratory capacity (wound healing assay,
Fig. 1D/E). Finally, CTRP9-281 and gCTRP9 exerted a comparable
anti-apoptotic (H2O2, 100 μm for 2 h) effect (TUNEL assay, Fig. 1F/G;
caspase cleavage, Fig. 1H/I).
The aforementioned results demonstrate CTRP9-281 exerts similar
or greater CBSC protection compared to gCTRP9. We next investigated
whether CTRP9-281 exerts its CBSC protective effect by similar or
distinctive mechanisms compared to gCTRP9. 23 mRNAs known to
involved in cell proliferation, migration, and survival were determined
by qT-PCR. Consistent with our recent report, gCTRP9 altered multiple

2. Methods
2.1. CBSCs isolation, identification, and in vitro studies
CBSCs were isolated from male enhanced green fluorescent protein
transgenic mice (The Jackson Laboratory) or littermate C57BL/6J con
trol mice as previously reported (Supplement Figure IA). Cells were
cultured in Dulbecco’s Modified Eagle Medium-F12-10% FBS. The pas
sage 2 CBSCs were tested for surface marker expression by flow
cytometry (BD LSR Fortessa) and differentiation potential. Passage 2
CBSCs express mesenchymal stem cells markers (such as CD105, Scal-1,
C-kit, and CD29), but not hematopoietic lineage marker CD45, or
endothelial cell marker CD31 (Supplemental Fig. 1A and 1B). Their
adipogenic and osteoblastic potential affirm pluripotency (Supple
mental Figure 1C).
2.2. Animal study protocol
All experiments were performed in adherence to the National In
stitutes of Health Guidelines on the Use of Laboratory Animals and were
approved by the Thomas Jefferson University Committee on Animal
Care. Permanent MI surgery was performed in adult male C57BL/6J
mice by ligating the left anterior descending coronary artery. Immedi
ately after MI, 1 × 105 enhanced green fluorescent protein CBSCs sus
pended in 25 μL PBS (containing 0.2 mM EDTA, pH = 7.3) were
administered via intramyocardial injection to the infarct border zone at
3 different sites. 30 min after MI, vehicle, g-CTRP9 (0.25 μg/g/d), or
CTRP9-281 (0.25 μg/g/d) was administrated via osmotic pump (peri
toneal implant) for 2 weeks. The number of CBSCs engrafted to the heart
1 and 3 days after transplantation was determined via green fluorescent
protein (GFP) immunostain as previously reported [5]. 6 weeks after MI,
cardiac function was evaluated via echocardiography followed by strain
3
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Fig. 2. Effect of CTRP9-281 gCTRP9 upon anti-oxidative and pro-angiogenic gene expression. A/B: Gene expression profile of CBSCs treated with vehicle,
gCTRP9, or CTRP9-281 (2 μg/ml, 24 h). n = 3/group. *P < 0.05. C/D, Western blots and quantification of protein expression in CBSCs cell lysis. N = 6/group, *P <
0.05. E/F, CBSCs (green) were fixed in vitro and immune-stained against VEGFA and FGF-2 (red). Nuclei are labeled with 4‘,6-diamidino-2-phenylindole (blue) and
scale bars, 10 μm. G/H: Western blots and quantification of VEGFA and FGF-2 in CBSCs cell lysis demonstrate that U0126 (an ERK1/2 activation inhibitor) blocked
CTRP9-281 induced VEGFA and FGF-2 expression (U0126: 10 μM 2 h before CTRP9-281 treatment) n = 4–5/group, *P < 0.05, **P < 0.01. (For interpretation of the
references to colour in this figure legend, the reader is referred to the Web version of this article.)

genes, with SOD2, SOD3, and Mmp9 being the three genes most signif
icantly upregulated (Fig. 2A and B). Similar to gCTRP9, CTRP9-281
upregulated these three anti-oxidative/pro-migratory genes (Fig. 2A
and B). Interestingly, we observed that CTRP9-281 had a unique prop
erty not shared by gCTRP9. CTRP9-281, not gCTRP9, significantly
upregulated vascular endothelial growth factor A (Vegfa) and basic
fibroblast growth factor (bFgf/Fgf2) (Fig. 2A and B). Western blots
analysis (Fig. 2C and D) and immunocellullar fluorescence analysis
(Fig. 2E and F) confirmed that CTRP9-281 significantly upregulated
VEGFA and FGF2 proteins expression.

The results presented in Fig. 1A and B demonstrated that CTRP9-281
significantly activated ERK1/2 in CBSC. To clarify the causative role of
ERK1/2 activation in CTRP9-281 gene/protein upregulation, we deter
mined the effect of ERK1/2 inhibitor upon CTRP9-281 upregulation of
pro-angiogenic proteins. ERK1/2 inhibition with U0126 (10 μM, 2 h
before CTRP9-281 treatment) virtually abolished the effect of CTRP9281 upon pro-angiogenic protein expression (Fig. 2G and H).
Taken together, these results demonstrate that CTRP9-281 is a bio
logically active polypeptide capable of upregulating anti-oxidant/proangiogenic gene expression in an ERK1/2-dependent fashion,
4
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Fig. 3. Effect of CTRP9-281 and gCTRP9 upon CBSC retention, angiogenesis, and fibrosis after MI. A/B: CTRP9-281 and gCTRP9 comparably increased CBSCs
survival in peri-infarct area 1 and 3 days after MI. EGFP CBSCs in the peri-infarct area was determined by the number of GFP positive cells per total nuclei (n = 20
from 4 mice). *P < 0.05; NS: not significant. C/D, CTRP9-281 plus CBSCs-treated animals have increased von Willebrand Factor + blood vessels near the infarct
border zone by 6 weeks post-MI. Slides from animals receiving MI + vehicle, MI + CBSC or MI + CBSC + gCTRP9 or MI + CBSC + CTRP9-281 injection were stained
for von Willebrand factor (purple) and α-sarcomeric actin (red). Nuclei are labeled with DAPI (blue) (n = 30 from 6 mice). *P < 0.05. E/F: Masson’s trichrome
staining revealed that the cardiac fibrotic area was significantly reduced by CBSC + CTRP9-281administration compared with MI group and CBSC + gCTRP9+. n =
6–9/group, *P < 0.05. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

significantly improving CBSC function and survival.

and CTRP9-281 alone (without CBSC) had similar protective effect
(Supplement Figure 2). Having demonstrated that CTRP9-281 stimu
lates VEGFA/FGF2 release by CBSC (in addition to a comparable effect
on anti-oxidant molecular expression shared with gCTRP9), we next
investigated whether CTRP9-281 may enhance CBSC cardioprotection
to greater degree than gCTRP9. First, the effect of CTRP9-281 and

3.2. CTRP9-281 enhances CBSC retention, promotes angiogenesis, and
exerts greater synergistic cardioprotection
Our pilot experiments demonstrated that administration of gCTRP9
5
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Fig. 4. CBSC þ CTRP9-281 exerts greater synergetic cardioprotection superior to CBSC þ gCTRP9. A/B: Representative echocardiographic images (A = M
mode, B=B mode) 6 weeks after MI. Three-dimensional regional wall strain diagrams showing contraction (orange/positive values) or relaxation (blue/negative
values) of 3 consecutive cardiac cycles. C: Strain analysis results of long-axis B-mode images. n = 10–12/group. *P < 0.05, **P < 0.01. D: Survival curves (n = 12/
group for sham and 27-45/group for MI). *P < 0.05, **P < 0.01. E: Left ventricular ejection fraction (LVEF), n = 10–18/group**P < 0.01. F: Heart weight/body
weight ratio (HW/BW). *P < 0.05, **P < 0.01. G: Lung weight/body weight ratio (LW/BW), n = 10–18. *P < 0.05, **P < 0.01. Survival curves were analyzed by
Gehan-Breslow-Wilcoxon test. LVEF were analyzed with 2-way ANOVA followed by a Bonferroni post hoc test. Other data were analyzed with 1-way ANOVA
followed by Bonferroni post hoc test. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

gCTRP9 upon CBSC retention, pro-angiogenic, and anti-fibrotic effects
were determined. CTRP9-281 increases CBSC retention to similar extent
as gCTRP9 (Fig. 3A and B). However, CTRP9-281 promoted CBSC
angiogenic (Fig. 3C/D) and anti-fibrotic effects (Fig. 3E and F) signifi
cantly greater than gCTRP9. Second, to determine whether the
enhanced pro-angiogenic and anti-fibrotic effects result in increased
cardioprotection, the effect of CTRP9-281 and gCTRP9 upon CBSC
cardiac function was determined by echocardiography followed by
strain analysis. Consistent with our previous report utilizing ADSC,
CBSC + gCTRP9 significantly improved cardiac function, as evidenced
by greater improvement of radial strain and longitudinal strain

(Fig. 4A–C). Importantly, CBSC + CTRP9-281 improved cardiac function
to greater degree than gCTRP9 (Fig. 4A–C). Third, we determined the
impact of CTRP9-281 and gCTRP9 upon CBSC-mediated survival and
remodeling effects. Compared to vehicle treated animals, CBSC +
gCTRP9 treatment significantly improved survival rate (Fig. 4D),
increased LVEF (Fig. 4E), reduced heart weight/body weight ratio
(Fig. 4F), and decreased lung weight/body weight ratio (Fig. 4G). More
importantly, CBSC + CTRP9-281 treatment markedly improved survival
rate, increased LVEF, and reduced lung weight/body weight ratio, to
greater extent than CBSC + gCTRP9 (P < 0.05, Fig. 4A-E/G). CBSC +
CTRP9-281 treatment reduced heart weight/body weight ratio to
6

D. Liu et al.

Redox Biology 41 (2021) 101929

(caption on next page)

7

D. Liu et al.

Redox Biology 41 (2021) 101929

Fig. 5. CTRP9-281 increases VEGF-enriched exosome biogenesis by CBSC. A: Nanosight test the number and size distribution of exosomes derived from the
CBSCs after PBS, gCTRP9 (2 μg/ml) and CTRP9-281 (2 μg/ml) treatment for 24 h n = 10–12/group, *P < 0.05, **P < 0.01. B: gCTRP9 and CTRP9-281 increase the
exosome biogenesis as evidenced by increased multivesicular body (MVBs) formation. CBSC were transfected with pCS2 hepatocyte growth factor-regulated tyrosine
kinase substrate (HRS)-RFP plasmid. Cells were treated with vehicle, gCTRP9 or CTRP9-281 for 24 h. The HRS-RFP positive MVBs were significantly increased in
CBSCs treatment with gCTRP9 and CTRP9-281 (n ≥ 5, One-Way ANOVA, **p < 0.01). C/D: Western blot showed the Exosome marker protein expression in CBSC
after gCTRP9 (2 μg/ml) and CTRP9-281(2 μg/ml) treatment for 24 h. U0126 (an ERK1/2 activation inhibitor) blocked CTRP9-281 and gCTRP9-induced exosome
biogenesis (U0126: 10 μM 2 h before CTRP9-281 treatment; n = 4–5/group). E: Western blot analysis of VEGFA, SOD2 and SOD3 expression in exosomes isolated
from vehicle, gCTRP9 and CTRP9-281 treated CBSC (1 × 106/well). n = 8/group, *P < 0.05 vs. vehicle. F. Western blot analysis of VEGFA, SOD2 and SOD3
expression in equal number of exosomes. n = 6/group.

greater extent than CBSC + gCTRP9 (although not statistically signifi
cant, Fig. 4F). Collectively, these results demonstrate CTRP9-281 has
greater synergistic cardioprotective effect with CBSC than gCTRP9,
likely due to its VEGF production/angiogenic properties.

production and resultant angiogenesis. Third, we demonstrated that
exosomes play a critical role in mediating CBSC-endothelial cell and
CBSC-cardiomyocyte communications, protecting the heart against
post-MI pathologic remolding (Fig. 7).
CTRP9 was initially discovered in adipocytes during efforts to
identify paralogs of adiponectin, an adipocyte-specific cytokine most
extensively investigated for its metabolic and cardioprotective actions
[22,23]. However, we and others recently demonstrate that CTRP9 is a
cardiokine, rather than an adipokine [14,15]. The adult heart expresses
the highest levels of CTRP9 of any organ, and CTRP9 is central in
maintaining local microenvironmental homeostasis. A recent study of
176 HF patients with 3-year follow-up demonstrates the association
between reduced plasma CTRP9 levels and increased mortality [24].
Experimental studies consistently demonstrate that plasma CTRP9 level
is significantly reduced in post-MI animals [25–30]. CTRP9KO signifi
cantly exacerbates post-MI pathological remolding [5]. Conversely,
CTRP9 supplementation attenuates acute ischemia/reperfusion injury,
post-MI pathologic ventricular remodeling, and IHF [14,27,28]. More
over, our recent study demonstrates that CTRP9 circulates in the plasma
primarily in the C-terminal globular domain isoform (gCTRP9) [31].
More importantly, gCTRP9, but not full length CTRP9, activates key
cardiac survival kinases, underlining the biologic importance of pro
teolytic cleavage of CTRP931. Finally, we recently demonstrate that
CTRP9 is critical in maintaining a healthy local environment in the
ischemic heart, enhancing survival of intramyocardial injected stem
cells, enabling their cardioprotection [5]. Collectively, strong and
consistent evidence from clinical observations and animal studies sup
ports CTRP9 as a cardioprotective cardiokine. However, the trans
lational application of gCTRP9 is limited due to difficulties in producing
biologically active protein and optimizing recombinant protein admin
istration dosage and route. Utilizing I-TASSER structure prediction and
3-D active site modeling followed by functional assays, we discovered a
CTRP9 C-terminal polypeptide retained biological activity similar to
gCTRP9. Similar to gCTRP9, CTRP9-281 upregulates antioxidative
molecules. additionally, CTRP9-281 upregulates pro-angiogenic gene
expression, significantly improving CBSC function and survival.
Stem cell therapy for the repair of damaged myocardium has evolved
into a promising treatment for ischemic heart disease. MSC-based
therapy, originating from bone marrow, adipose tissue, or umbilical
cord cells, continues to gain consent and appeal because of the large
body of preclinical evidence supporting greater paracrine cardiorepar
ative potential. However, poor survival of donated stem cells and failure
of stem cell engraftment in the damaged organ pose significant chal
lenges. Increased understanding of the mechanisms enhancing stem cell
migration and survival in the microenvironment of the injured
myocardium is imperative to improve both cell repair capacity and
therapeutic application strategies. We recently demonstrate that CTRP9
is critical in maintaining a healthy microenvironment, facilitating ADSC
engraftment in infarcted myocardial tissue and enhancing ADSC car
dioprotective efficacy. Specifically, CTRP9KO markedly impaired ADSC
survival/retention, whereas gCTRP9 supplementation improves ADSC
survival/retention, protecting against post-MI remodeling [5]. In the
present study, we demonstrated that although CTRP9-281 has similar
potency to gCTRP9 in improving CBSC survival and retention,
CTRP9-281 has greater synergistic protective effect with CBSC than
gCTRP9. Mechanistic investigation demonstrates that CTRP9-281

3.3. CTRP9-281 increases SOD2/VEGFA-enriched exosome biogenesis by
CBSC, contributing to its cardioprotective action
Our results demonstrate CTRP9-281 is uniquely pro-angiogenic,
contributing to its synergistic protective effect with CBSC. Consider
able evidence exists that cancer cells promote angiogenesis and tumor
growth by releasing VEGF-rich exosomes [20]. To determine whether
exosomes are involved in CTRP9-281-enhanced CBSC angiogenesis and
cardioprotection, several experiments were performed. First, the effect
of gCTRP9 and CTRP9-281 upon CBSC (1 × 106/well) exosome pro
duction was determined by Nanosight300 and Red fluorescence
labeled-HRS (hepatocyte growth factor-regulated tyrosine kinase sub
strate, a multivesicular body marker). CTRP9-281 increases exosome
numbers to greater extent than gCTRP9 (Fig. 5A and B). Neither gCTRP9
nor CTRP9-281 significantly altered exosome size (Fig. 5A). Second,
previous studies demonstrate that ERK1/2 regulates exosome biogenesis
[21]. We therefore investigated the effect of U0126 (10 mM, 2 h before
gCTRP9 or CTRP9-281 treatment) upon CBSC exosome production by
surrogate exosome markers, including CD9, TSG101, Flot, and CD63.
Although CTRP9-281 stimulated exosomes greater than gCTRP9,
pre-treatment with U0126 equally blocked such effects (Fig. 5C/D).
Third, to determine whether VEGFA is carried by CBSC-derived exo
somes (as observed in cancer cells [20]), exosomes were isolated from
vehicle-, gCTRP9-, or CTRP9-281-treated CBSC. Both gCTRP9 and
CTRP9-281 significantly increased exosomes containing SOD2/SOD3.
CTRP9-281, but not gCTRP9, significantly increased VEGFA levels in
CBSC-derived exosomes (Fig. 5E/F).
In a final attempt to determine the role of exosomes in CTRP9-281mediated enhancement of CBSC cardioprotection, two additional ex
periments were performed. First, adult cardiomyocytes were treated
with exosomes isolated from vehicle, gCTRP9, or CTRP9-281 treated
CBSC. Their effect upon H2O2 (100 μM for 2 h) induced apoptosis was
determined. Exosomes isolated from CTRP9-281 treated CBSC exerted
superior anti-apoptotic effect compared to that from gCTRP9 treated
CBSC (Fig. 6A). Second, CBSC was pre-treated with GW4869 (an exo
some biogenesis inhibitor) before intramyocardial injection. GW4869
pre-treatment significantly attenuated CBSC + CTRP9-281 car
dioprotection, as determined by cardiac fibrosis (Fig. 6B) and function
(Fig. 6C and D). Taken together, these results provide evidence that
exosomes derived from CTRP9-281 pre-treated CBSCs contribute to
CBSC cardiac protection.
4. Discussion
Three novel observations are notable in the current study. First, we
identified the first CTRP9 c-terminal polypeptide (CTRP9-281) pos
sessing similar or greater activity than the native cleaved c-terminal
globular domain of CTRP9 (gCTRP9) in improving CBSC function. Sec
ond, we provided the first in vivo evidence that CTRP9-281 in concert
with CBSC exerts more synergistic cardioprotective effect than gCTRP9
plus CBSC, likely due to CTRP9-281’s unique promotion of CBSC VEGFA
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Fig. 6. Exosomes mediate gCTRP9/CTRP9-281 enhancement of CBSC cardioprotection. A: Western blots and quantification protein expression utilizing adult
mouse cardiomyocytes cell lysis. Cardiomyocytes were treated with exosomes isolated from gCTRP9 or CTRP9-281 treated CBSCs for 24h followed by H2O2
treatment for 2 h *P < 0.05, **P < 0.01. B-D: CBSC were pre-treated with neutral sphingomyelinase-2 (nSMase2) inhibitor GW4869 (2 μg/ml) before their
intramyocardial injection. GW4869 attenuated the synergistic anti-fibrotic (B) and cardiac functional improvement (C/D) effect of CTRP9-281 and CBSC. n = 6–10/
group, *P < 0.05.

stimulation of VEGFA production by CBSC and the resultant
pro-angiogenic effect is likely responsible for the augmented car
dioprotective function of CTRP9-281.
Although it was once believed that mesenchymal stem cells could
generate new cardiac tissue, evidence now suggests that mesenchymal
stem cell therapy releases cardioprotective factors which activate
endogenous pathways, facilitating myocardial repair-not de novo

cardiomyocyte generation [32]. Recent studies demonstrate these fac
tors may cluster into extracellular vesicles, particularly exosomes, which
transfer proteins, microRNAs, and lipids to cardiomyocytes, mediating
cardioprotection [33,34]. Unfortunately, the reparative capacity of
mesenchymal stem cells significantly declines post-MI, as these cells
from post-MI patients possess decreased cardioprotective capability
[35–37]. Strategies capable of improving the reparative secretome will
9
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Fig. 7. Graphic illustration of synergistic cardioprotection of CTRP9-281 plus CBSC and its underlying molecular mechanisms.

restore mesenchymal stem cell cardioreparative capability. Moreover,
defining the paracrine mechanisms mediating the beneficial effects of
mesenchymal stem cell therapy may lead to clinically attractive cell-free
therapeutic options. Our current study demonstrated that treatment of
CBSC with CTRP9-281 significantly increases SOD-rich and VEGFA-rich
exosome production. Treatment with exosomes isolated from
CTRP9-281 pre-treated CBSC significantly attenuated oxidative
stress-induced cardiomyocyte death. Moreover, pre-treatment of CBSC
with exosome biogenesis inhibitor abolished the synergistic effect of
CBSC and CTRP9-281. These results are consistent with the notion that
cancer cells promote angiogenesis and tumor growth via VEGF-rich
exosomes [20].
It should be noted that although both gCTRP9 and CTRP9-281
significantly activate ERK1/2, CTRP-281, not gCTRP9, upregulates
Vegfa and Fgf2 expression. Mechanisms responsible for this differential
signaling effect are likely complex and requires extensive molecular/
cellular/in vivo investigations. One possible explanation is that addi
tional signaling steps are present between ERK1/2 activation and Vegfa
and Fgf2 expression. CTRP9-281, not gCTRP9, may activate the mole
cules required for ERK1/2-mediated Vegfa and Fgf2 expression. This
possibility will be investigated in our future study.
In summary, we identified the first CTRP9 c-terminal polypide
(CTRP9-281) with strong biological activity. It shares the anti-oxidant/

cell survival effects with gCTRP9, promoting CBCS retention after
intramyocardial injection. Additionally, CTRP9-281 promotes VEGFArich exosome production from CBSC, and exerts augmented angio
genic and cardioprotective effect when co-administered with CBSC in
the infarcted heart. Collectively, these results demonstrate that CTRP9281 may have important translational value in mesenchymal stem cell
therapy against ischemic cardiac injury.
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